# Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

> **NCT06385236** · PHASE4 · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 120 (estimated)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **BIOLOGICAL:** Dupilumab
- **BIOLOGICAL:** Benralizumab

## Key facts

- **NCT ID:** NCT06385236
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06385236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06385236, "Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06385236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*